NUVISAN - A fully integrated CRO / CDMO since 1979
The NUVISAN group is a Contract Research Organization (CRO) and Contract Manufacturing Organization (CDMO) with its headquarters in Neu-Ulm and six sites in Germany and France (Neu-Ulm, Berlin, Grafing, Gauting, Waltrop and Sophia-Antipolis) in addition to monitoring activities with offices in Argentina, Peru and Brazil as well as in the USA.
NUVISAN offers integrated and coupled services and solutions along the drug development value chain from target identification to the patient with all supporting services (DMPK, GMP synthesis, formulation development and analysis, bioanalysis, Phase 1 CPU, clinical trial supplies and monitoring).
With our proven track record spanning 40 years of continuous service is a testimony to the operational excellence and the experience of our 1.000 highly qualified employees.
From July 2020 NUVISAN grew to support early discovery through the acquisition of a complete research unit from Bayer, which brings new capabilities to the NUVISAN group and its clients, as well as the addition of approximately 400 scientists. The early discovery service expansion empowers NUVISAN to further deliver a strategy to provide “all from a single source” solutions from early research and preclinical services (including lead structure development, medicinal chemistry, pharmacology, drug metabolism and pharmacokinetics and toxicology) to services focused on clinical phase I and phase II/ III research.
With a refined and clear service strategy, the NUVISAN group is today one of the fastest growing companies in the industry for the benefit of its partners and the patients they are working to cure. NUVISAN prides itself on providing a highly collaborative and strategic service solution from early Biotech to the top 10 pharmaceutical companies and venture capital firms in the industry.